464 related articles for article (PubMed ID: 15137320)
1. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
4. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
7. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
9. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
[TBL] [Abstract][Full Text] [Related]
11. Pro PSA : a "pro cancer" form of PSA?
Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
[TBL] [Abstract][Full Text] [Related]
12. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
Abrahamsson PA; Kuriyama M
Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
[TBL] [Abstract][Full Text] [Related]
13. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
Wymenga LF; Mensink HJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
[TBL] [Abstract][Full Text] [Related]
14. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
[TBL] [Abstract][Full Text] [Related]
15. [proPSA: a precursor of prostate-specific antigen, may improve the early diagnosis of prostate cancer].
Sela BA; Doolman R
Harefuah; 2011 May; 150(5):466-9, 489. PubMed ID: 21678645
[TBL] [Abstract][Full Text] [Related]
16. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Mikolajczyk SD; Rittenhouse HG
Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
18. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
[TBL] [Abstract][Full Text] [Related]
19. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
